Charles E Mahan

Summary

Publications

  1. doi request reprint Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event
    Charles E Mahan
    University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA
    Thromb Haemost 106:405-15. 2011
  2. doi request reprint A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents
    Charles E Mahan
    Presbyterian Healthcare Services, University of New Mexico, 1100 Central Ave SE, Albuquerque, NM, 87106, USA
    J Thromb Thrombolysis 37:271-8. 2014
  3. doi request reprint Venous thromboembolism pharmacy intervention management program with an active, multifaceted approach reduces preventable venous thromboembolism and increases appropriate prophylaxis
    Charles E Mahan
    University of New Mexico Health Sciences Center, College of Pharmacy, University of New Mexico, Albuquerque, NM 87131 0001, USA
    Clin Appl Thromb Hemost 18:45-58. 2012
  4. doi request reprint New antithrombotics: the impact on global health care
    Charles E Mahan
    University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87111, USA
    Thromb Res 127:518-24. 2011
  5. doi request reprint Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population
    Charles E Mahan
    Presbyterian Healthcare Services, University of New Mexico, Albuquerque, NM, USA
    Thromb Res 132:520-6. 2013
  6. doi request reprint Identifying, monitoring and reducing preventable major bleeds in the hospital setting
    Deborah Caraballo
    New Mexico Heart Institute, University of New Mexico, 502 Elm Street NE, Albuquerque, NM 87102, USA
    J Thromb Thrombolysis 36:7-13. 2013
  7. doi request reprint Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates
    Charles E Mahan
    New Mexico Heart Institute, University of New Mexico College of Pharmacy, Albuquerque, New Mexico 87102, USA
    Thromb Haemost 108:291-302. 2012
  8. doi request reprint The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation
    Allison Burnett
    University of New Mexico Hospital, Inpatient Pharmacy Department, Albuquerque, NM, USA
    Expert Opin Pharmacother 14:1119-33. 2013
  9. doi request reprint Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization
    Charles E Mahan
    1Department of Outcomes Research, New Mexico Heart Institute, Albuquerque, NM, USA
    Clin Appl Thromb Hemost 19:504-12. 2013
  10. doi request reprint Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery
    Charles E Mahan
    Department of Outcomes Research, New Mexico Heart Institute, University of New Mexico, 502 Elm Street NE, Albuquerque, NM 87102, USA
    Pharmacotherapy 32:1036-48. 2012

Detail Information

Publications12

  1. doi request reprint Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event
    Charles E Mahan
    University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA
    Thromb Haemost 106:405-15. 2011
    ..8 to $52 billion, $6.8 to $36 billion, and $3.4 to $27 billion, respectively...
  2. doi request reprint A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents
    Charles E Mahan
    Presbyterian Healthcare Services, University of New Mexico, 1100 Central Ave SE, Albuquerque, NM, 87106, USA
    J Thromb Thrombolysis 37:271-8. 2014
    ..Protamine is used in a wide array of procedures. Evaluating protamine's current use may be beneficial in identifying roles for future UFH and LMWH reversal agent use. ..
  3. doi request reprint Venous thromboembolism pharmacy intervention management program with an active, multifaceted approach reduces preventable venous thromboembolism and increases appropriate prophylaxis
    Charles E Mahan
    University of New Mexico Health Sciences Center, College of Pharmacy, University of New Mexico, Albuquerque, NM 87131 0001, USA
    Clin Appl Thromb Hemost 18:45-58. 2012
    ..0006). In conclusion, a pharmacy-led multifaceted intervention can significantly increase the rates of appropriate prophylaxis and significantly reduce the incidence of preventable VTE in hospitalized patients...
  4. doi request reprint New antithrombotics: the impact on global health care
    Charles E Mahan
    University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87111, USA
    Thromb Res 127:518-24. 2011
    ..Clinicians should be vigilant concerning these agents and be prepared to inform patients and make decisions with their use...
  5. doi request reprint Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population
    Charles E Mahan
    Presbyterian Healthcare Services, University of New Mexico, Albuquerque, NM, USA
    Thromb Res 132:520-6. 2013
    ..Medically ill, hospitalized patients are at increased risk for venous thromboembolism (VTE) after discharge. This study aimed to examine thromboprophylaxis patterns, risk factors, and post-discharge outcomes...
  6. doi request reprint Identifying, monitoring and reducing preventable major bleeds in the hospital setting
    Deborah Caraballo
    New Mexico Heart Institute, University of New Mexico, 502 Elm Street NE, Albuquerque, NM 87102, USA
    J Thromb Thrombolysis 36:7-13. 2013
    ..Similar programs should be explored prospectively on a larger scale to reduce harm from anticoagulants in the hospital setting...
  7. doi request reprint Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates
    Charles E Mahan
    New Mexico Heart Institute, University of New Mexico College of Pharmacy, Albuquerque, New Mexico 87102, USA
    Thromb Haemost 108:291-302. 2012
    ..The cost models may be utilised to estimate other countries' costs or VTE-specific disease states...
  8. doi request reprint The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation
    Allison Burnett
    University of New Mexico Hospital, Inpatient Pharmacy Department, Albuquerque, NM, USA
    Expert Opin Pharmacother 14:1119-33. 2013
    ..Unfortunately, because of the complexity of warfarin therapy and potential for adverse events (AEs), many patients who might benefit go untreated or receive suboptimal therapy, increasing their stroke and/or bleeding risk...
  9. doi request reprint Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization
    Charles E Mahan
    1Department of Outcomes Research, New Mexico Heart Institute, Albuquerque, NM, USA
    Clin Appl Thromb Hemost 19:504-12. 2013
    ..Hospitalized medically ill patients receiving antithrombotic medications experience increased risk of bleeding. We examined antithrombotic use, bleeding rates, and associated risk factors at 30 days post discharge...
  10. doi request reprint Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery
    Charles E Mahan
    Department of Outcomes Research, New Mexico Heart Institute, University of New Mexico, 502 Elm Street NE, Albuquerque, NM 87102, USA
    Pharmacotherapy 32:1036-48. 2012
    ..In this article, we review the burden of VTE in patients undergoing major orthopedic surgery, highlight the differences in the guidelines, and examine the new anticoagulants as they are related to VTE prophylaxis in this patient group...
  11. doi request reprint Regulatory, policy and quality update for venous thromboembolism and stroke in United States hospitals
    Charles E Mahan
    New Mexico Heart Institute, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA
    Thromb Res 130:586-90. 2012
    ..This review provides a brief history, overview, and update for the development of quality measures, quality systems, and regulatory and policy changes as related to stroke and VTE within the US healthcare system...
  12. doi request reprint Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing
    Charles E Mahan
    Cardinal Health Pharmacy Solutions, Lovelace Medical Center, Lovelace Rehabilitation Hospital, Lovelace Health Systems, 601 Dr Martin Luther King Jr Ave NE, Albuquerque, NM, 87102, USA
    Intern Emerg Med 5:299-306. 2010
    ..Newly published risk-assessment models may be beneficial in determining which patients would best benefit from BID UFH or TID UFH...